GLP-1 Medications for Insulin Resistance and Prediabetes: Are They Right for You?

GLP-1 medications can improve blood sugar and support weight management when they fit your medical needs. But having insulin resistance or prediabetes doesn’t automatically mean you need one. The right decision considers your health history, treatment goals, possible side effects, and a plan for caring for yourself over time.

There can absolutely be a time and place for medication. There also needs to be a conversation that goes beyond the number on the scale.

What Do GLP-1 Medications Do?

GLP-1 is a hormone your body naturally releases in response to eating. Medications called GLP-1 receptor agonists act on the same receptors.

They can help your body release insulin when blood sugar rises, reduce glucagon signaling, slow stomach emptying, and influence appetite.

You may recognize names such as:

• Semaglutide: Ozempic, Rybelsus, and Wegovy.
• Liraglutide: Victoza and Saxenda.
• Tirzepatide: Mounjaro and Zepbound.

Tirzepatide is often included in conversations about GLP-1s, but it acts on two hormone receptors: GIP and GLP-1.

The brand matters. Products with the same active ingredient can have different approved uses, doses, and formulations. They are not interchangeable prescriptions.

Can They Help With Insulin Resistance?

They can help improve glucose regulation, and treatment-related weight loss can improve insulin sensitivity for some people. But they don’t make insulin resistance disappear permanently or remove the need for ongoing care.

If you’re still learning the basics, start with my insulin resistance overview.

The more useful question is:

“Given my health situation, would this medication offer benefits that outweigh its risks and treatment burden?”

That answer can differ for someone with type 2 diabetes, someone with obesity and prediabetes, and someone with insulin resistance who doesn’t meet another treatment indication.

What If You Have Prediabetes?

Research is encouraging, particularly for people who have both obesity and prediabetes.

In the three-year SURMOUNT-1 analysis, participants with obesity and prediabetes received tirzepatide or a placebo. By 176 weeks, type 2 diabetes had developed in:

• 1.3% of participants taking tirzepatide
• 13.3% of participants taking placebo

Those results suggest substantial potential to delay progression in that population. They don’t mean everyone with prediabetes needs tirzepatide, or that treatment permanently prevents diabetes after it stops. Read the study.

For some people, nutrition support, physical activity, a diabetes prevention program, and possibly metformin may be appropriate options. Others may also be candidates for weight-management medication.

Your A1C is part of the conversation, along with your overall risk, medical history, preferences, and access to treatment.

You can read more about the starting points in my prediabetes guide.

Who May Be a Candidate?

For adult weight-management treatment, commonly used eligibility criteria include:

• A BMI of 30 or higher
• A BMI of 27 or higher with at least one weight-related health condition

These criteria help establish eligibility. They don’t replace a full health assessment or mean everyone who qualifies should take medication.

GLP-1 medications are also used for type 2 diabetes, where treatment eligibility is not limited to those weight-management thresholds.

Wanting to lose a few pounds, by itself, is not a medical indication. That’s different from treating obesity or another qualifying condition with medication.

And choosing appropriate medication isn’t a personal failure. You don’t need to prove your worth by struggling without support.

What If You Have Type 2 Diabetes?

For women with type 2 diabetes, these medications can be part of a glucose-management plan. Depending on the medication and your health history, benefits may extend beyond weight loss.

Certain products have evidence and approved uses involving cardiovascular or kidney outcomes in specific populations.

Your healthcare provider should also review:

• Insulin and sulfonylureas: Doses may need adjustment to reduce low-blood-sugar risk.
• Diabetic retinopathy: Existing eye disease may require closer monitoring.
• Kidney health and hydration: Vomiting or diarrhea can lead to dehydration and kidney problems.

Don’t adjust your diabetes medications on your own. Ask what needs to change and how you should monitor your blood sugar.

What If You Have PMOS/PCOS?

PMOS, formerly known as PCOS, often involves insulin resistance. That makes GLP-1 medications an understandable topic of interest.

The international guideline says medications such as liraglutide or semaglutide may be considered for higher-weight management in adults with the condition, alongside lifestyle support and under general eligibility guidance.

That does not mean every woman with PMOS needs a GLP-1. While research is ongoing, PMOS itself is not yet a specific FDA-approved indication for these medications.

The discussion should include:

• Your glucose levels and other metabolic health concerns
• Whether you meet an approved treatment indication
• Other options, including nutrition support and metformin when appropriate
• Side effects, cost, and the possibility of long-term treatment
• Contraception and pregnancy plans

Research into reproductive effects is evolving. These medications should not be presented as established fertility treatments. Read the international guideline recommendations.

Are They Used for Other Conditions?

Some products have additional approved uses. Examples include:

• Wegovy: Reducing major cardiovascular events in adults with established cardiovascular disease and overweight or obesity.
• Ozempic: Reducing certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease.
• Zepbound: Treating moderate-to-severe obstructive sleep apnea in adults with obesity.
• Wegovy injection: Treating certain adults with MASH, an inflammatory liver condition, and moderate-to-advanced fibrosis.

These are specific indications with specific eligibility requirements. Having any heart, kidney, liver, or sleep condition doesn’t automatically mean a GLP-1 is appropriate.

What Precautions Matter?

Nausea, constipation, diarrhea, vomiting, and uncomfortable fullness can occur. More serious problems are less common, but they deserve attention.

Before starting, review these issues with your healthcare provider:

• Personal or family history of medullary thyroid carcinoma or MEN2: Semaglutide and tirzepatide are contraindicated in these situations.
• Severe gastroparesis: These medications may be unsuitable because they slow stomach emptying.
• Pancreatitis or gallbladder problems: Discuss your history and symptoms that need prompt evaluation.
• Eating disorders or difficulty eating enough: Include these in the assessment and support plan.
• Upcoming procedures: Tell your anesthesia team you take a GLP-1.

Persistent severe abdominal pain, repeated vomiting, or inability to keep fluids down should not be brushed off as “just the medication.” Contact your healthcare provider promptly; symptoms of a serious allergic reaction require emergency care.

Pregnancy Plans Deserve Their Own Conversation

GLP-1 medications are not weight-loss treatments for pregnancy.

If pregnancy is possible, talk about contraception and a medication plan before trying to conceive.

Two details worth knowing:

• Semaglutide: For weight management or cardiovascular risk reduction, prescribing information advises stopping at least two months before a planned pregnancy.
• Tirzepatide: Oral hormonal contraception may be less effective. Prescribing information advises switching to a non-oral method or adding a barrier method for four weeks after starting and four weeks after each dose increase.

If you become pregnant or are breastfeeding, contact your prescriber for medication-specific guidance.

A Smaller Appetite Still Needs a Nutrition Plan

Eating less isn’t automatically the same as eating well.

When appetite drops, it can become harder to get enough protein, energy, fluids, and other nutrients. A helpful plan may include:

• Smaller meals at regular times
• Protein spread throughout the day
• Foods you tolerate during nausea or fullness
• Adequate fluids and gradual adjustments to fiber
• Resistance training to support muscle and strength

Protein needs should be individualized, particularly if you have kidney disease. And protein alone doesn’t replace strength training.

The goal is to support your health and function while treatment works—not see how little you can eat. The joint nutrition advisory on GLP-1 treatment emphasizes nourishment, managing side effects, and preserving muscle and bone.

What Happens If You Stop?

Weight regain is common after stopping treatment. Appetite can return, and some blood sugar and other metabolic improvements may diminish.

In the STEP 1 extension, participants regained about two-thirds of the weight they had lost within one year after semaglutide and the study’s lifestyle intervention stopped. That means two-thirds of their previous weight loss, not two-thirds of their body weight. Read the study.

In SURMOUNT-4, people switched from tirzepatide to placebo gained an average of 14% relative to their weight at withdrawal over the following year, despite ongoing lifestyle support. Read the study.

Regain isn’t proof that someone lacked willpower. These medications treat conditions that can require continuing care.

Before stopping, plan for:

• Changes in appetite and meal routines
• Blood sugar monitoring and medication review
• Ongoing nutrition and activity support
• Follow-up if weight or other health measures change

Those steps can support health and maintenance efforts, but they cannot guarantee that weight regain won’t happen.

Questions to Ask Before Starting

Bring these to your next appointment:

• What condition are we treating, and what benefits should I expect?
• Why this medication rather than another option?
• Does my medical history or pregnancy timeline change the recommendation?
• How will we manage side effects and make sure I’m eating enough?
• What will we monitor besides weight?
• What happens if insurance stops covering it or I need to discontinue it?

You deserve a clear plan that fits your health and your life.

This article is for educational purposes and does not replace individualized medical advice. Talk with your healthcare provider before starting, stopping, or changing medication.

Sources and Further Reading

• Wegovy prescribing information
• Zepbound prescribing information
• FDA: Cardiovascular risk reduction with Wegovy
• FDA: Wegovy for MASH
• FDA 2025 approvals: Ozempic kidney indication
• ADA Standards of Care 2026: Obesity and Weight Management